Skip to main content

Molecular diagnostics have revolutionized healthcare by enabling scientists and healthcare professions to identify disease with higher sensitivity while also elucidating specific mechanisms of disease progression. Unfortunately, the complexity associated with these tests severely hinders their implementation in regions where resources are limited. Thus, there is a current unmet need for simple molecular diagnostics that can be deployed in the most remote healthcare settings at minimal cost. Further, we have also demonstrated that simplification can ultimately unlock new functionalities in molecular analysis, thus advancing our endeavor to understand the most complex diseases, including cancer.

Dr. Scott Berry has 10 years of experience developing molecular diagnostics in both academia and industry. His technologies have been used to analyze a wide range of disease states, including cancer, HIV, tuberculosis, hepatitis, influenza, transplant rejection, and malaria. To date, molecular diagnostics developed by Dr. Berry have been used to analyze over 7,000 clinical samples, including blood, urine, sputum, plasma, and biopsied tissue.

email scott.berry@uky.edu for alt text

Biomedical Engineering Society's 2022 annual meeting

Our team from the University of Kentucky did a great job at the Biomedical Engineering Society's 2022 annual meeting in San Antonio this year! They ga

2022 Annual Meeting Banner - BMES

BMES 2022

August 2022 - Congratulation to our team members that have been selected to present their recent works at BMES 2022. The BMES annual meeting will be h